EarningsQ2 2026 Earnings Report
MX:DGX Q2 2026 EPS Results
Actual EPS$53.74
Consensus EPS$48.62
Beat/MissBeat by +$5.12
One Year Ago EPS$45.13
MX:DGX Q2 2026 Revenue Results
Actual Revenue$52.41B
Expected Revenue$51.20B
Beat/MissBeat by +$1.21B
YoY Revenue Growth+10.21%
Earnings Announcement Details
QuarterQ2 2026
Date07/23/2026
TimeBefore Open
Conference CallThursday, July 23, 2026
MX:DGX Upcoming Earnings
Quest Diagnostics's next earnings date is estimated for October 22, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:DGX Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented strong operational and commercial momentum: double-digit revenue growth, robust volume expansion, notable diagnostic and commercial milestones (Haystack MRD approval, Flatiron integration), meaningful adjusted EPS growth (+19.1%) and a raised full-year guide. Offsetting these positives are short-term margin pressures (70 bps headwind in Q2 from Nova ramp, Corewell/Fresenius mix and deferred compensation), higher expected H2 costs (fuel and Nova), and regulatory reimbursement risk (PAMA uncertainty and a ~30 bps ACA headwind). On balance, the positives (top-line strength, EPS improvement, raised guidance, product/partnership milestones, and productivity/automation investments) significantly outweigh the headwinds.Company Guidance
Strong Top-Line Growth
Consolidated revenues of $3.04 billion, up 10.2% year-over-year; consolidated organic revenue growth of 10.0%; Diagnostic Information Services revenue up 10.3% (10.1% organic).
Robust Volume Expansion
Total requisition volume increased 13.1% year-over-year (organic +13%); Corewell Health and Fresenius Medical Care relationships contributed 9% to volume; excluding those two relationships, volumes grew 4.1%.
Meaningful EPS and Profitability Gains
Reported EPS of $2.84 versus $2.47 prior year; adjusted EPS of $3.12 versus $2.62 prior year (adjusted EPS growth 19.1%; excluding a one-time tax benefit, adjusted EPS growth was 15.3%).
Raised Full-Year Guidance
Updated 2026 revenue guidance increased to $11.95–$12.05 billion (growth 8.3%–9.2%); reported EPS guide $9.97–$10.17; adjusted EPS guide $11.05–$11.25; cash from operations expected ~ $1.8 billion; CapEx ~ $550 million.
Commercial and Clinical Momentum
Double-digit revenue growth across several advanced diagnostic areas (cardiometabolic, brain health, liver fibrosis, autoimmune); questhealth.com delivered robust consumer revenue growth and uptake of new services (e.g., thyroid test).
Haystack MRD and Oncology Distribution Wins
Haystack MRD received New York State approval (enables nationwide commercial efforts); became the largest reference lab to extend Haystack access through Flatiron Health integration with a pilot at American Oncology Network and planned roll-out to ~4,700 clinicians.
Operational Improvements via Automation and AI
Progress on Invigorate target of 3% annual cost savings; expanded lab automation (WholeLogix Genius digital diagnostic system installed at additional sites), launched IntelliDraw for specimen collection, and are deploying other AI tools to improve productivity and supply ordering.
Cash Generation and Balance Sheet Trends
Cash from operations year-to-date $875 million vs. $858 million prior year; share count expected slightly below 2025 and interest expense expected to be consistent with 2025.
MX:DGX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed